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The aim of type 1 diabetes mellitus (DM) management is to achieve 
glycaemic control by frequent exogenous insulin injections. To 
maintain fasting blood glucose levels within near to the normal 
range of 3.9 - 5.6 mmol/L, frequent insulin dose adjustments may 
be required. Insulin replacement is achieved by short-, intermediate- 
and long-acting insulin formulations, depending on the patient’s 
individual circumstances and the treating healthcare professional’s 
clinical judgement. One clinical strategy of glycaemic control is 
through intensive insulin therapy (IIT). However, patients on IIT have 
been observed to experience weight gain over time, regardless of the 
level of glycaemic control achieved.[1] Several mechanisms have been 
postulated to account for this, including snacking outside normal 
mealtimes to offset IIT-associated hypoglycaemia. In addition, anabolic 
effects of insulin on skeletal muscle, alterations in the regulators of 
adiposity, and the resolution of glycosuria leading to conservation 
of calories in previously poorly controlled patients with DM are also 
hypothesised as mechanisms of weight gain over time in type 1 DM.[2]
Newer insulin formulations attempt to mimic physiological secre-
tion of insulin by changing the onset and duration of action of 
insulin. However, these analogues are expensive and not available in 
the South African (SA) public health sector. The older human insulin 
formulations used in this setting have less favourable onset and 
duration of action profiles and are therefore associated with a greater 
degree of weight gain in most settings.[3]
Objective
To determine the effect of human insulin therapy, adjusted every 
3 months to control blood glucose, on body mass index (BMI) in 
a cohort of type 1 DM patients at the Kalafong Hospital Diabetes 
Clinic in Pretoria, SA. In addition, the study sought to determine the 
differential effects of sex on BMI changes in response to exogenous 
human insulin dose adjustments to control blood glucose levels.
Methods
The study utilised prospectively collected data on a cohort of type 1 
DM patients seen at the clinic for at least 2 years. All patients were 
clinically managed and data were collected on administrative forms 
in a structured way. The patients had to be at least 18 years of age on 
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Background. To maintain fasting blood glucose levels within near to the normal range in type 1 diabetes mellitus (DM), frequent insulin 
dose adjustments may be required with short-, intermediate- and long-acting insulin formulations. Patients on human insulin generally 
experience weight gain over time, regardless of the level of glycaemic control achieved.
Objectives. To determine the effects of human insulin, adjusted quarterly to achieve glycaemic control, on body mass index (BMI), and 
establish dose regimens that achieve optimal glycaemic control without increasing BMI in patients with type 1 DM at the Kalafong Diabetes 
Clinic in Pretoria, South Africa.
Methods. The sample size (N=211, 48.8% male) was obtained by non-probability convenience sampling of all available records of patients 
with type 1 DM aged ≥18 years at baseline at the clinic. The longitudinal relationships of covariates with time-varying BMI, as well as with 
time-varying glycated haemoglobin (HbA1c) levels, were explored using multilevel mixed-effects linear regression modelling.
Results. The majority of the patients (84.8%) received the twice-daily biphasic human insulin regimen and the remainder received the 
basal neutral protamine Hagedorn (NPH) plus prandial regular human insulin regimen. The multivariable multilevel mixed-effects linear 
regression model indicated that time-varying BMI was significantly positively related to time-varying twice-daily biphasic insulin dosage 
(β (standard error) 0.464 (0.190), p=0.015), baseline HbA1c (0.092 (0.026), p<0.001) and baseline BMI (0.976 (0.016), p<0.001). There were 
significant inverse associations with the number of years spent in the study (–0.108 (0.052), p=0.038), time-varying HbA1c (–0.154 (0.031), 
p<0.001) and male sex (–0.783 (0.163), p<0.001). There were non-significant negative longitudinal associations of age (–0.005 (0.006), 
p=0.427) and current smoking status (–0.231 (0.218), p=0.290) with BMI outcomes.
Conclusions. There was no evidence that optimal quarterly-prescribed daily dosage adjustments of insulin improved and maintained blood 
glucose control without increasing body weight. When compared with the basal NPH plus prandial insulin regimen, twice-daily biphasic 
insulin was associated with a statistically significant  increase in subsequent BMI. Baseline HbA1c and BMI were also significantly positively 
associated with time-varying BMI. However, males appeared to be at a lower risk than females of an increase in BMI during insulin therapy. 
A question for further research is whether the analogue insulins will be associated with the same increase in BMI, as well as the same modest 
improvements in HbA1c, seen in this sample.
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first encounter at the clinic and not on metformin and/or acarbose, co-
exposure to which was considered a potential confounder in the asso-
ciation between exogenous human insulin exposure and BMI changes 
owing to their potentially weight-reducing effects in other settings.[4,5]
Patients were excluded from the study if they failed to attend more 
than two consecutive or three random non-consecutive scheduled 
quarterly clinic visits during the period of observation. Patients were 
assessed at least quarterly between 2009 and 2014. All clinic data, 
from which individual patient information was extracted, were also 
routinely captured onto a clinic database. Data were extracted and 
captured on an Excel spreadsheet (2010, Microsoft, USA) for data 
cleaning and arrangement. The final dataset was exported to Stata 
version 12 (StataCorp, USA) for statistical analysis.
Statistical analysis
The following variables were utilised in the analysis: quarterly-
prescribed daily human insulin dosages (IU/kg/d); mean daily 
human insulin dose exposures (IU/d); type of human insulin 
regimen prescribed (twice-daily biphasic or basal neutral protamine 
Hagedorn (NPH) plus prandial normal insulin regimen); measured 
weight and height (from which time-varying BMI was calculated); 
baseline weight and time-invariant height (from which baseline BMI 
was calculated); baseline glycated haemoglobin (HbA1c) level (%; 
mmol/mol); time-varying HbA1c level (%; mmol/mol) measured 
semi-annually; sex; age at the onset of the study and going forward; 
smoking history; and time spent in the study.
Further data management and analysis was carried out using Stata 
version 12. Baseline patient characteristics were summarised using 
means and standard deviations (SDs) for continuous variables and 
frequencies for count variables. The t-test and χ2 test (or Fisher’s exact 
test when there were insufficient numbers in cells for the χ² test, and 
the Welch test when the equal variance assumption was not satisfied) 
were used to evaluate differences in baseline characteristics by sex 
and HbA1c levels.
The longitudinal relationship of time-varying BMI with time-
varying glycaemic control, adjusted for exogenous human insulin 
replacement and other covariates, was examined by multilevel mixed-
effects linear regression analysis, which accounted for the correlated 
repeated measurements of covariates within subjects.
Ethical approval
Ethical approval was obtained from the University of Pretoria 
Institutional Ethics Committee (ref. no. 94/2015). At their first visit, 
all clinic patients are requested to sign a notification that informs 
them that routinely collected information at the clinic may be used for 
research purposes, that all information used is strictly confidential, 
and that no patient identifiers will be made known. Consent to access 
routinely collected patient information for this study was obtained 
from the Kalafong Hospital chief executive officer as the custodian of 
the clinic data (‘Permission to conduct research’ letter dated 6 March 
2015). All patient information was used anonymously.
Results
Patient flow, exclusion and inclusion were performed as shown in Fig. 1.
The final sample consisted of 211 patients (108 females and 103 
males). The mean (SD) age was 43.1 (14.4) years (range 18 - 78). The 
mean baseline BMI and HbA1c for the sample were 27.8 (5.5) kg/m2 
and 10.2% (3.5%), respectively. Most patients were at >8.0% HbA1c 
levels at baseline (65.9%) and most were prescribed the twice-daily 
biphasic insulin regimen (84.8%) (Table 1).
Baseline characteristics stratified by sex (Table 2) indicated that 
females had a higher baseline BMI than males (p=0.002), at a mean 
Table 1. Baseline characteristics of the patients (N=211)
Age at first visit (yr), mean (SD) 43.1 (14.4)
Duration of type 1 DM (yr) (N=131),  
mean (SD)
15.5 (7.7)
Clinic visits (n), mean (SD) 20.7 (6.7)
Time in study (yr), mean (SD) 4.7 (1.6)
Weight (kg), mean (SD) 75.5 (15.0)
BMI (kg/m2), mean (SD) 27.8 (5.5)
HbA1c (%), mean (SD) 10.2 (3.5)
BMI category (kg/m²), n (%)
<19 10 (4.7) 
20 - 25 66 (31.3)
25.1 - 30 73 (34.6)
30.1 - 35 44 (20.9)
35.1 - 40 14 (6.6)
> 40 4 (1.9)
HbA1c (% (mmol/mol)), n (%)
≤8.0 (≤64) 72 (34.1) 
>8.0 (>64) 139 (65.9)
Mean daily insulin dose and regimen,  
mean (SD), n (%)
 Basal NPH + prandial regular insulin 
(IU/d)
59.8 (36.7), 32 (15.2)
Twice-daily biphasic insulin only (IU/d) 49.4 (17.1), 179 (84.8)
Smoking status, n (%)
 Never smoked or stopped (> and  
<1 year ago)
174 (82.5)
Currently smoking 37 (17.5)
SD = standard deviation; DM = diabetes mellitus; BMI = body mass index;  
HbA1c = glycated haemoglobin; NPH = neutral protamine Hagedorn.
Patients with DM identied from all records at 
the Kalafong Hospital Diabetes Clinic, 2009 - 2014
N=1 146
Patients with type 1 DM included in 
the rst preliminary sample
n=493
Patients with type 1 DM included in 
the second preliminary sample
n=470
Final sample 
(n=108 females (51%), 
n=103 males (49%))
n=211
Patients with type 1 DM excluded owing 
to short observation time (<2 years) and a 
pre-specied number and pattern of missed 
scheduled visits
n=259
Patients with type 1 DM excluded 
owing to age at baseline (<18 years)
n=23
Patients excluded owing to type 2 
DM or exposure to metformin and/
or acarbose
n=653
Fig. 1. Patient sampling description for inclusion and exclusion in the study. 
(DM = diabetes mellitus.)
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(SD) of 28.9 (6.2) and 26.5 (4.4) kg/m², respectively. Females had a 
higher baseline HbA1c level than males (mean 10.8% (3.8%) v. 9.5% 
(3.0%); p=0.01), and more males than females were current smokers 
(28.1% v. 7.4%; p<0.001). There were no statistically significant 
differences by sex in the duration of type 1 DM, the number of clinic 
visits and time of observation in the study (Table 3).
Table 2. Baseline characteristics of the patients stratified by sex
Variables Females (N=108, 51.2%) Males (N=103, 48.8%) p-value
Age (yr), mean (SD) 41.9 (16.2) 44.3 (12.1) 0.222
Height (cm), mean (SD) 159.8 (6.7) 171.3 (7.8) <0.001
Weight (kg), mean (SD) 73.6 (16.2) 77.5 (13.4) 0.063
BMI (kg/m2), mean (SD) 28.9 (6.2) 26.5 (4.4) 0.002
HbA1c (%), mean (SD) 10.8 (3.8) 9.5 (3.0) 0.010
BMI category (kg/m²), n (%) 0.012
<19 4 (3.7) 6 (5.8)
20 - 25 30 (27.7) 36 (34.9)
25.1 - 30 31 (28.7) 42 (40.8)
30.1 - 35 28 (25.9) 16 (15.5)
35.1 - 40 11 (10.2) 3 (2.9)
>40 4 (3.7) 0 (0)
HbA1c (% (mmol/mol)), n (%) 0.407
≤8.0 (≤64) 34 (31.5) 38 (36.9)
>8.0 (>64) 74 (68.5) 65 (63.1)
Insulin regimen and daily dose, mean (SD), n (%)
Basal NPH + prandial regular insulin (IU/d) 65.9 (47.5), 17 (15.7) 52.9 (25.1), 15 (14.6) 0.350
Twice-daily biphasic insulin (IU/d) 48.8 (17.7), 91 (84.3) 50.1 (16.6), 88 (85.4) 0.614
Smoking status, n (%) <0.001
Never smoked 93 (86.1) 41 (39.8)
Stopped >1 yr ago 5 (4.6) 27 (26.2)
Stopped <1 yr ago 2 (1.9) 5 (4.9)
Currently smoking 8 (7.4) 29 (28.1)
SD = standard deviation; BMI = body mass index; HbA1c = glycated haemoglobin; NPH = neutral protamine Hagedorn.
Table 3. Further patient characteristics stratified by sex
Variables Females (N=108, 51.2%) Males (N=103, 48.8%) p-value
Duration of type 1 DM (yr) (N=131), mean (SD) 16.1 (7.9) (n=60) 15.1 (7.6) (n=71) 0.457
Clinic visits (n), mean (SD) 20.1 (6.9) 21.3 (6.4) 0.218
Time in study (yr), mean (SD) 4.6 (1.7) 4.9 (1.5) 0.182
DM = diabetes mellitus; SD = standard deviation.
Table 4. Baseline patient characteristics stratified by baseline HbA1c level
Variables
HbA1c ≤8.0%  
(N=72, 34.1%)
HbA1c >8.0%  
(N=139, 65.9%) p-value
Age (yr), mean (SD) 44.9 (16.0) 42.1 (13.4) 0.199
Height (cm), mean (SD) 166.3 (9.3) 164.9 (9.1) 0.311
Weight (kg), mean (SD) 78.8 (13.7) 73.8 (15.4) 0.023
BMI (kg/m²), mean (SD) 28.6 (5.2) 27.2 (5.7) 0.079
Sex, n (%) 0.407
Female 34 (31.5) 74 (68.5)
Male 38 (36.9) 65 (63.1)
Insulin regimen daily dose, mean (SD)
Basal NPH + prandial regular insulin (IU/d) 57.1 (25.0) 65.4 (33.0) <0.001
Twice-daily biphasic insulin (IU/d) 49.4 (17.7) 55.6 (17.7) <0.001
Smoking status, n (%) 0.045
Never smoked 41 (30.4) 94 (69.6)
Stopped >1 yr ago 18 (56.3) 14 (43.7)
Stopped <1 yr ago 2 (28.6) 5 (71.4)
Currently smoking 11 (29.7) 26 (70.3)
HbA1c = glycated haemoglobin; SD = standard deviation; BMI = body mass index; NPH = neutral protamine Hagedorn.
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There were no significant differences by age, height or sex between 
patients in the lower and higher baseline HbA1c levels (Table 4). 
Also stratified by baseline HbA1c level (Table 5), the proportion of 
patients in the >8.0% HbA1c category was significantly higher for the 
group with longer duration of type 1 DM (mean (SD) 16.9 (7.7) years 
(54.2%) than for those with a shorter onset of type 1 DM  at 13.5 (7.4) 
years (45.8%) (p=0.014). Higher doses of twice-daily biphasic insulin 
were prescribed to patients at higher baseline HbA1c levels (>8.0%) 
than to those with HbA1c levels of ≤8.0% (mean 55.6 (17.7) IU/d v. 
49.4 (17.7) IU/d; p<0.001). Similarly, higher doses of basal NPH plus 
prandial regular insulin were prescribed to patients at higher baseline 
HbA1c levels (>8.0%) than to those with HbA1c levels of ≤8.0% 
(mean 65.4 (33.0) IU/d v. 57.1 (25.0) IU/d; p<0.001).
Apart from the expected statistically significant and very high 
correlations between total insulin exposure and exposure to either 
the biphasic (r=0.959) or basal NPH plus prandial regular insulin 
regimens (r=1.000) and subsequent BMI and baseline BMI (r=0.889), 
other correlations were also observed at p<0.05. For instance, 
subsequent HbA1c and baseline HbA1c were moderately correlated 
(r=0.509). The number of clinic visits was dropped from multivariate 
analysis owing to high correlation with time spent in the study 
(r=0.869) (Appendix 1).
For multilevel mixed-effects linear regression modelling, the 
variables of baseline BMI, baseline and time-varying HbA1c and 
age were modelled as continuous variables. Insulin regimen, sex and 
smoking history were modelled as categorical variables. The variable 
smoking history was categorised into two descriptive classes. Age 
and smoking status in the final reduced model, albeit not statistically 
significant, contributed favourably to goodness-of-fit characteristics 
and the lowest information criteria statistics and were therefore 
included in the final model[6] (Table 6).
Exposure to the twice-daily biphasic insulin regimen, adjusted for 
other variables including total insulin exposure, was associated with 
a 0.464 kg/m2 (p=0.015) increase in subsequent BMI when compared 
with the basal-bolus insulin regimen. After adjustment for other 
variables, the BMI increased by 0.009 kg/m2 for every unit increase 
of any human insulin per day (p=0.009). After adjustment for other 
variables, the following covariables: an additional year of observation; 
every 1.0% increase in HbA1c (poor glycaemic control); and being 
male, were associated with a decrease in BMI (β (standard error)) 
of 0.108 (0.052) kg/m2 (p=0.038), 0.154 (0.031) kg/m2 (p<0.001) and 
0.783 (0.163) kg/m2 (p<0.001), respectively. However, every 1 kg/m2 
higher baseline BMI predicted a 0.98 kg/m2 increase in subsequent 
BMI. Every 1.0% higher baseline HbA1c predicted a 0.09 kg/m2 
increase in subsequent BMI (Table 6). Adjusted increasing age 
and current smoking status were associated with statistically non-
significant reductions in subsequent BMI in this cohort of –0.005 
(0.006) (p=0.427) and –0.231 (0.218) (p=0.290), respectively.
Discussion
This study described longitudinal associations of time-varying BMI 
with exposure to quarterly-prescribed daily insulin dosage regimens 
in an attempt to achieve optimal blood glucose control in a sample of 
patients with type 1 DM at the Diabetes Clinic at Kalafong Hospital, 
Table 6. Regression models by time-varying BMI value
Univariate models Multivariate model
Time-varying BMI value covariates β (SE) p-value β (SE) p-value
Age 0.142 (0.007) <0.001 –0.005 (0.006) 0.427*
Baseline BMI (kg/m2) 0.983 (0.009) <0.001 0.976 (0.016) <0.001
Time-varying HbA1c (%) –0.333 (0.061) <0.001 –0.154 (0.031) <0.001
Baseline HbA1c (%) –0.151 (0.031) <0.001 0.092 (0.026) <0.001
Number of clinic visits –0.046 (0.018) 0.010 Dropped owing to collinearity  
with time in study
Time in study 0.022 (0.014) 0.128 –0.108 (0.052) 0.038
Sex
0 = female Ref Ref
1 = male –3.262 (0.203) <0.001  –0.783 (0.163) <0.001
Insulin regimen
0 = basal NPH + prandial regular insulin (IU/day) Ref Ref
1 = twice-daily biphasic insulin (IU/d) 2.664 (0.257) <0.001 0.464 (0.190) 0.015
Total insulin exposure (IU/d) 0.029 (0.005) <0.001 0.009 (0.003) 0.009
Smoking status
0 = never smoked and stopped > or <1 yr ago Ref Ref
1 = currently smoking –2.251 (0.293) <0.001 –0.231 (0.218) 0.290*
Constant n/a  2.111(0.667) 0.002
Multivariate model information criteria statistics:
Model AIC = 5 628.996 (v. 5 729.69 without the ‘age’ and ‘smoking’ variables in the full model).
Model BIC = 5 684.904 (v. 5 775.59 without the ‘age’ and ‘smoking’ variables in the full model).
BMI = body mass index; SE = standard error; HbA1C = glycated haemoglobin; NPH = neutral protamine Hagedorn; n/a = not applicable.
*Statistically non-significant covariates included in the final multivariable model owing to an improvement in model information criteria statistics.
Table 5. Further patient characteristics stratified by baseline HbA1c level
Variables HbA1c ≤8.0% (N=72, 34.1%) HbA1c >8.0% (N=139, 65.9%) p-value
Duration of type 1 DM (yr) (N=131), mean (SD) 13.5 (7.4) (n=60) 16.9 (7.7) (n=71) 0.014
Clinic visits (n), mean (SD) 22.4 (6.1) 19.8 (6.8) 0.007
Time in study (yr), mean (SD) 5.2 (1.5) 4.5 (1.7) 0.003
HbA1c = glycated haemoglobin; DM = diabetes mellitus; SD = standard deviation.
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Pretoria. Sex differences in outcomes of exogenous human insulin 
replacement therapy were also investigated.
On multivariable multilevel linear mixed-effects regression 
analysis, there was no evidence that optimal quarterly-prescribed 
daily dosage increases of insulin safely improved and maintained 
blood glucose control without increasing body weight. Both regimens 
consistently and independently increased weight, particularly in 
female patients, without clinically significantly improving blood 
glucose control.[7] The study also found that higher baseline BMI and 
HbA1c predicted weight gain regardless of insulin regimen.
There were significant sex differences in the change in body weight 
on exposure to any insulin used to control blood glucose to optimal 
levels. Male patients tended to experience reductions in time-varying 
BMI on exposure to the twice-daily biphasic human insulin regimen, 
after adjustment for the other variables in the model. Twice-daily 
human insulin was the treatment regimen prescribed for 84.8% of 
patients in this cohort and was proportionally distributed the same 
in both males and females.
The study did not find a balance between optimal glycaemic 
control and prevention of weight gain. Instead, exposure to human 
insulin to achieve glycaemic control consistently predicted weight 
gain in the cohort observed. However, in a 2010 review, Hahr and 
Molitch[8] observed that optimal glycaemic control in type 1 DM 
patients depended on an insulin regimen that closely mimicked 
endogenous insulin secretion. The study found that this was best 
achieved with long-acting basal insulin to maintain normal fasting 
glucose levels, and multiple daily injections of short- or rapid-
acting (prandial) insulin with meals. Furthermore, the choice of 
regimen depended on the individual needs and circumstances of the 
patient, as well as the treating health professional’s judgement.[8] This 
assertion was consistent with that of Fullerton et al.[9] that there was 
then (in 2014) no firm evidence for specific blood glucose targets, 
therefore necessitating individualised therapeutic goals that take into 
account the patient’s age, disease progression, macrovascular risk, 
lifestyle and disease self-management capabilities. The reviewers 
also concluded that patient-specific regimens to optimise glycaemic 
control have been made possible by the development of insulin 
analogues, which increase flexibility and control in the treatment of 
type 1 DM. Also, because IIT with basal NPH and prandial human 
insulin requires multiple daily injections, it was crucial that health 
workers communicate therapy-related issues to patients. These issues 
include lifestyle adjustments and exercise, meal intake and its effects, 
proper insulin self-administration, and the effects of insulin dose 
adjustments not based on reliable blood glucose readings.[9] These 
therapy-related issues[8,9] were found to be adequately addressed in 
the Kalafong Diabetes Clinic practice.
The current study concluded that exposure to adjusted doses of 
human insulin to achieve optimal glycaemic control in patients with 
type 1 DM resulted in a statistically significant increase in BMI. This 
relationship seemed to be more prominent in female patients and 
in patients with higher baseline HbA1c levels and BMI categories. 
Conclusions can also be drawn that an increase in BMI is consistent 
with improvements in blood glucose control in this setting. Also, 
strategies already in place at the Kalafong Diabetes Clinic to control 
weight gain through advice on physical exercise, dietary and lifestyle 
counselling as part of clinical management should continue and be 
strengthened further to sustain optimal BMI outcomes in type 1 DM 
patients in this setting.
The finding that a higher baseline HbA1c predicted a larger 
and statistically significant increase in subsequent BMI in patients 
exposed to the twice-daily biphasic insulin dosage regimen when 
compared with the basal NPH plus prandial regular insulin regimen 
group in this study population was consistent with observations 
by Nansel et al.,[10] Williams et al.[11] and Conway et al.[1] These 
researchers found that IIT and a higher baseline HbA1c were 
predictors of weight gain in patients in their respective settings. The 
current study also identified any insulin exposure adjusted for other 
covariates and baseline BMI to be significant predictors of weight 
gain in the cohort of patients observed. These findings are consistent 
with those of Conway et al.[1] in a longitudinal study to determine the 
prevalence and incidence of overweight and obesity in a cohort of 589 
type 1 DM patients followed up over at least 18 years.
The Diabetes Control and Complications Trial cited in the review 
by Kaufman[2] also demonstrated the association between excess 
weight gain and IIT. The risk factors suggested by the review include 
oral glucose ingestion to offset hypoglycaemia, the fear of nocturnal 
hypoglycaemia resulting in night-time snacking, the anabolic effect 
of insulin on skeletal muscle mass, and alteration in the leptin-
mediated regulators of lipolysis and lipogenesis,[2] also resulting in 
resistance to the antilipolytic actions of insulin.[12] Conservation 
of calories in previously poorly controlled diabetic patients is 
hypothesised as another mechanism of weight gain in patients 
with type 1 DM. According to this hypothesis, this conservation of 
ingested calories occurs when glycosuria is resolved with improved 
glycaemic control during IIT to blood glucose levels below the renal 
secretion threshold.[2]
Where the results of this study may not be wholly consistent 
with those of other published studies on the topic, Nansel et al.[10] 
advise that most differences of associations between studies can be 
attributed to differences in sample characteristics, study designs 
and statistical analytical methods. They also found the association 
between BMI and glycaemic control to be complex, highlighting 
the need for longitudinal study designs and appropriate analyses 
to account for the time-dependent direction of causation of the 
observed association. The current longitudinal multilevel study 
design has attempted to characterise that complex relationship in the 
observed sample of patients.
This was an observational study of primary data routinely collected 
for clinical management of patients with type 1 DM in a clinic 
setting. The data were therefore not collected explicitly for answering 
the research question. As a result, there were a number of missing 
measurements, either not recorded or not measured. The variable 
most affected was weight measurements at each quarterly visit, which 
was manually observed to follow an ‘item non-response’ missingness 
distribution.[13] This variable was, however, not imputed for randomly 
missing data, but was rather analysed as is without the 27.6% missing 
measurements, to avoid possible measurement bias. It is therefore 
highly probable, based on the literature, that the observed magnitude 
of BMI increase in this sample was underestimated by the missing 
27.6% quarterly-repeated weight measurements in the sample.
The study was also not conducted on newly diagnosed or 
previously untreated patients. An inception cohort with only newly 
diagnosed patients in the study would have avoided ‘prevalent user 
bias’ introduced by ‘survivors’ of the time-varying effects on BMI 
of pre-observation exposure to human insulin.[14] Together, these 
limitations could have attenuated the observed BMI effects of insulin 
in this sample. Also, findings from the current study are limited to a 
single ethnic and demographic group of black African patients and 
may therefore not be generalisable beyond those confines.
Unmeasured covariates at the beginning of exposure to human 
insulin in this cohort were probably subsequently affected by the 
exposure itself.[14] For instance, patients may have changed their 
dietary habits after diagnosis, which would be expected to impact on 
BMI outcomes in variable ways. When not measured and adjusted 
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for, this covariate could be expected to confound the true change 
in measured subsequent BMI. This limitation is consistent with 
that recognised in the Nansel et al.’s[10] study that no diet or physical 
activity data were available to determine their contribution to time-
varying BMI in particular.
Many regression models in epidemiological (and clinical) research 
are replete with instances of collinearity.[15] This is because many 
observed covariates often ‘share common physiological mechanisms 
or measure different aspects of the same underlying mechanism’. [15] 
However, despite the observed sign reversals and evidence of 
mediation seen from the univariate to the multivariate models 
in Table 6, exploration of the impact of multicollinearity on the 
modelling process was beyond the scope of the current study and 
was not undertaken. However, owing to collinearity between the 
number of patient visits to the clinic and the number of years of 
follow-up in the study, the number of patient visits to the clinic was 
excluded from the final model. This decision served to prevent too 
much explanatory redundancy introduced by including two clearly 
collinear time-based explanatory covariables in the model.[16]
Conclusion
Based on the literature reviewed for this study, there does not seem 
to be a dosage range at which optimal glycaemic control can be 
achieved easily without an increase in body weight. Rather, optimal 
glycaemic control, through adjustments of exogenous insulin 
replacement therapy based on measured HbA1c levels, appears 
to be a consistent and independent predictor of an increase in 
body weight. Regular attendance of scheduled clinic visits may be 
advisable to ensure better BMI outcomes, especially in females. It 
could also be advised that BMI increase may not necessarily be 
bad for HbA1c control, but should be tightly controlled through 
exercise and dietary advice, and closely monitored to prevent 
relevant comorbidities.
No patients in this study were on analogue insulins. These 
include the rapid-acting aspart, lispro and glulisine analogues, the 
long-acting basal glargine and detemir analogues, and the premixed 
insulin analogue formulations. These types of insulin have been 
formulated to more closely mimic a normal insulin release profile. [3] 
However, the DM treatment protocol at Kalafong Hospital is similar 
to that currently in other SA government hospitals in that only 
human insulins are available, and not the more physiologically 
compatible analogue insulins. These analogues may be much better 
than the traditional human insulin currently used in the Kalafong 
Diabetes Clinic with regard to weight gain. Successful management 
of type 1 DM relies on how closely the prescribed regimen mimics 
normal physiological insulin release patterns.[3] A question for 
further research is whether the analogue insulins will result in the 
same increase in BMI, as well as the same modest improvements in 
HbA1c, seen in this sample.
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Covariable pairwise correlation matrix analysis




D  –0.155  –0.155  –0.119 1.000
E  –0.086  –0.175  –0.194 0.509 1.000
F 0.869  –0.132  –0.224 1.000
G  –0.274  –0.200 0.168  –0.143 0.091 1.000
H  –0.116  –0.103  –0.052  0.405 1.000
I  0.349  0.413 0.072  –0.194  –0.018 0.090 0.099 0.092 1.000
J 0.105  0.084 0.084 0.094 0.065 0.062 1.000
K  0.116  0.104 0.080 0.072 0.076 0.087 0.959 1.000
L  –0.448  –0.488  –0.449 1.000 0.493 1.000
A = body mass index (BMI); B = base BMI; C = clinic visits; D = glycated haemoglobin (HbA1c); E = base HbA1c, F = time in study; G = sex; H = smoking status; I = age; J = total insulin; 
K = biphasic insulin; L = basal plus prandial insulin.
Only r-values significant at p<0.05 are shown.
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